The Body Covers: The 8th Conference on Retroviruses and Opportunistic Infections
Clinical Trials of HIV-1 Reverse Transcriptase Inhibitors
February 6, 2001
These 41 patients who had viral loads <500 and median CD4 counts of 568 were then followed for an additional 40-48 weeks with the understanding that they would be given nelfinavir, efavirenz, and new NRTI if they failed. How many remained stable after five years of stability? 59% continued to have RNA <50 copies/mL. This could be predicted somewhat by the baseline viral loads on entry into the new trial, as 77% of the patients on entry who had lower viral loads with at least one value below 50 maintained this virological stability. None of the nine patients whose viral loads wavered between 50 and 500 copies achieved this increased stability. These patients also maintained stable CD4 counts.
This study is actually of limited value to me, although it helps me understand that the patients who are stable and have viral loads <50 copies/mL will probably maintain stability and the higher viral loads. I am trying hard to think of a common clinical problem this study is answering and I find that it just doesn't answer any. Patients who are stable with superb viral control can stay on any regimen they are on if it is not toxic and effective. I feel slightly reassured to see that, but I think we all knew that already.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.